J Rheum Dis.  2020 Oct;27(4):270-276. 10.4078/jrd.2020.27.4.270.

Evaluation of Dry Eye Syndrome in Patients With Familial Mediterranean Fever: A Cross-sectional Study

• Şaş S
• Kurt A
• Kurt EE
• Koçak FA
• Erdem HR

• KMID: 2506980
• DOI: http://doi.org/10.4078/jrd.2020.27.4.270

Abstract

Objective
. It has been reported that some autoimmune diseases are associated with dry eye syndrome. There are limited studies that relates dry eye syndrome in patients with Familial Mediterranean fever (FMF). The aim of this study is to evaluate the relationship between dry eye syndrome in patients with FMF comparing with healthy controls. Methods. Prospective cross-sectional study was carried out in departments of physical medicine and rehabilitation and ophthalmology clinics in a tertiary public institution with a sample of 46 participants including 23 FMF patients and 23 healthy controls. Detailed eye examination was performed in all cases and indicators of xerophthalmia were assessed by Schirmer-I test, tear break-up time (TBUT) and ocular surface disease index (OSDI). In patient group; results of FMF gene analysis, acute phase reactants, concomitant diseases and number of FMF attacks were noted. Results. The average Schirmer-I test results for right-eye were recorded as 14.74±8.38 for the FMF group and 13.09±10.54 for the healthy group; the TBUT scores were 14.69±5.32 in FMF group and 15±6.45 in the healthy group; and OSDI scores were 9.04±2.75 and 10.86±1.77 in the FMF group and the healthy control, respectively. There were no statistically significant differences between FMF and control groups in terms of Schirmer-I, TBUT, and OSDI scores (all p＞0.05). No correlation was identified between acute phase reactants and the OSDI, TBUT and Schirmer-I tests for right-eye (all p＞0.05). Conclusion. This study identified no correlation between dry eye and FMF. Ocular pathology is rare and infrequently reported in FMF.

Keyword

Familial mediterranean fever; Dry eye syndrome; Inflammation; Xerophthalmia

Reference

1. Samuels J, Ozen S. 2006; Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol. 18:108–17. DOI: 10.1097/01.bor.0000198006.65697.5b. PMID: 16344627.

2. Sarı İ, Birlik M, Kasifoğlu T. 2014; Familial Mediterranean fever: an updated review. Eur J Rheumatol. 1:21–33. DOI: 10.5152/eurjrheum.2014.006. PMID: 27708867. PMCID: PMC5042258.

3. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Turkish FMF Study Group. 2005; Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 84:1–11. DOI: 10.1097/01.md.0000152370.84628.0c. PMID: 15643295.

4. Petrushkin H, Stanford M, Fortune F, Jawad AS. 2016; Clinical review: familial Mediterranean fever-an overview of pathogenesis, symptoms, ocular manifestations, and treatment. Ocul Immunol Inflamm. 24:422–30. DOI: 10.3109/09273948.2015.1010012. PMID: 25760918.

5. Tarabishy AB, Hise AG, Traboulsi EI. 2012; Ocular manifestations of the autoinflammatory syndromes. Ophthalmic Genet. 33:179–86. DOI: 10.3109/13816810.2012.695421. PMID: 22924780.

6. Salehzadeh F, Yasrebi O, Hosseini Khotbesara M, Hosseini Khotbesara M. 2014; Idiopathic uveitis and familial Mediterranean fever: is there any relationship? Autoimmune Dis. 2014:238931. DOI: 10.1155/2014/238931. PMID: 24592325. PMCID: PMC3926436.

7. Yazici A, Ozdal P, Yuksekkaya P, Elgin U, Teke MY, Sari E. 2014; Ophthalmic manifestations in familial Mediterranean fever: a case series of 6 patients. Eur J Ophthalmol. 24:593–8. DOI: 10.5301/ejo.5000398. PMID: 24338581.

8. Zoukhri D. 2006; Effect of inflammation on lacrimal gland function. Exp Eye Res. 82:885–98. DOI: 10.1016/j.exer.2005.10.018. PMID: 16309672. PMCID: PMC1361268.

9. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. 2007; STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 282:9358–63. DOI: 10.1074/jbc.C600321200. PMID: 17277312.

10. Mankan AK, Kubarenko A, Hornung V. 2012; Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol. 167:369–81. DOI: 10.1111/j.1365-2249.2011.04534.x. PMID: 22288580.

11. Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. 1999; Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol. 26:1983–6. PMID: 10493680.

12. Huang JF, Zhang Y, Rittenhouse KD, Pickering EH, McDowell MT. 2012; Evaluations of tear protein markers in dry eye disease: repeatability of measurement and correlation with disease. Invest Ophthalmol Vis Sci. 53:4556–64. DOI: 10.1167/iovs.11-9054. PMID: 22695964.

13. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. 2012; Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 154:63–71. DOI: 10.1016/j.ajo.2012.01.034. PMID: 22541929. PMCID: PMC3378826.

14. Ben-Zvi I, Livneh A. 2014; Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the Anakinra trial. Isr Med Assoc J. 16:271–3. PMID: 24979828.

15. Türkyilmaz K, Küçükali Türkyilmaz A, Kurt A, Kurt EE, Sevim MŞ, Oner V. 2013; Investigation of tear osmolarity in early rheumatoid arthritis: relation to disease activity. Can J Ophthalmol. 48:235–9. DOI: 10.1016/j.jcjo.2013.03.014. PMID: 23931459.

16. Karalezli A, Borazan M, Yilmaz S, Kiyici H, Akova YA. 2009; Conjunctival impression cytology and tear-film changes in patients with familial Mediterranean fever. Acta Ophthalmol. 87:39–43. DOI: 10.1111/j.1755-3768.2008.01437.x. PMID: 19094172.

17. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. 1997; Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 40:1879–85. DOI: 10.1002/art.1780401023. PMID: 9336425.

18. 2007; The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 5:75–92. DOI: 10.1016/S1542-0124(12)70081-2. PMID: 17508116.

19. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. 2000; Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 118:615–21. DOI: 10.1001/archopht.118.5.615. PMID: 10815152.

20. Irkec MT. Turkish OSDI Study Group. 2007; Reliability and validity of Turkish translation of the Ocular Surface Disease Index (OSDI) in dry eye syndrome. Investig Ophthalmol Vis Sci. 48:408.

21. Lazar M, Rothkoff L. 2010; Colchicine and ocular surface changes in familial Mediterranean fever. Acta Ophthalmol. 88:e5. author reply e6. DOI: 10.1111/j.1755-3768.2009.01652.x. PMID: 19681787.

22. Alster Y, Varssano D, Loewenstein A, Lazar M. 1997; Delay of corneal wound healing in patients treated with colchicine. Ophthalmology. 104:118–9. DOI: 10.1016/S0161-6420(97)30352-2. PMID: 9022114.

23. Leibovitch I, Alster Y, Lazar M, Langevitz P, Livneh A, Loewenstein A. 2003; Corneal wound healing in a patient treated with colchicine for familial Mediterranean fever (FMF). Rheumatology (Oxford). 42:1021–2. DOI: 10.1093/rheumatology/keg261. PMID: 12869680.

24. Leibovitch I, Alster Y, Scherrmann JM, Azmon B, Barequet IS, Livneh A, et al. 2003; Colchicine in tear fluid of treated patients with familial Mediterranean fever. Cornea. 22:191–3. DOI: 10.1097/00003226-200304000-00001. PMID: 12658080.

25. Mori S, Yonemura K, Migita K. 2013; Familial Mediterranean fever occurring in an elderly Japanese woman with recent-onset rheumatoid arthritis. Intern Med. 52:385–8. DOI: 10.2169/internalmedicine.52.9102. PMID: 23370751.

26. Tanaka M, Migita K, Miyashita T, Maeda Y, Nakamura M, Komori A, et al. 2007; Coexistence of familial Mediterranean fever and Sjögren's syndrome in a Japanese patient. Clin Exp Rheumatol. 25:792.

27. Akkoc N, Sari I, Akar S, Binicier O, Thomas MG, Weale ME, et al. 2010; Increased prevalence of M694V in patients with ankylosing spondylitis: additional evidence for a link with familial Mediterranean fever. Arthritis Rheum. 62:3059–63. DOI: 10.1002/art.27598. PMID: 20533539.

28. Yildiz G, Kayatas M, Uygun Y, Timuçin M, Candan F. 2010; Coexistence of systemic lupus erythematosus and familial Mediterranean fever. Intern Med. 49:767–9. DOI: 10.2169/internalmedicine.49.3102. PMID: 20424368.

29. Kaya S, Kaptanoglu E, Elden H, Hizmetli S. 2010; Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med. 49:619–22. DOI: 10.2169/internalmedicine.49.2777. PMID: 20228604.

30. Haznedaroglu S, Oztürk MA, Sancak B, Goker B, Onat AM, Bukan N, et al. 2005; Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol. 23(4 Suppl 38):S77–80. PMID: 16273770.

31. Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, et al. 2013; Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 131:715–23. DOI: 10.1001/jamaophthalmol.2013.195. PMID: 23599118. PMCID: PMC4167802.

32. Sgrignoli MR, Silva DA, Nascimento FF, Sgrignoli DAM, Nai GA, da Silva MG, et al. 2019; Reduction in the inflammatory markers CD4, IL-1, IL-6 and TNFα in dogs with keratoconjunctivitis sicca treated topically with mesenchymal stem cells. Stem Cell Res. 39:101525. DOI: 10.1016/j.scr.2019.101525. PMID: 31430719.

33. Kim DJ, Lim CY, Gu N, Park CY. 2017; Visual fatigue induced by viewing a tablet computer with a high-resolution display. Korean J Ophthalmol. 31:388–93. DOI: 10.3341/kjo.2016.0095. PMID: 28914003. PMCID: PMC5636714.